PHL Treatment in Pancreatic Cancer

Running, not enrolling · Early Phase 1

Conditions studied: Pancreatic Ductal Adenocarcinoma

In brief

This proposal will investigate the effect of paricalcitol, hydroxychloroquine, and losartan (PHL) combination of 3 stroma-modifying drugs on pancreatic adenocarcinoma and its stroma.

Key facts

Study ID
NCT05365893
Run by
Fox Chase Cancer Center
People needed
20
Starts
2021-10-20
Expected to finish
2026-12-31
Last updated by the study team
2026-05-22

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.